A controlled trial of erythromycin in adults with nonstreptococcal pharyngitis

C. J. MCDonald, W. M. Tierney, Siu Hui, M. L. French, D. S. Leland, R. B. Jones

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The local physician has long been maligned for profligate use of antibiotics in treating infections of the upper-respiratory-tract and pharyngitis. Academic medicine always 'knew' that the only important bacterial, and therefore treatable, cause of 'strep' pharyngitis was streptococcus. But the recent continued discovery of new and difficult-to-culture bacterial pathogens [1-3] reminds us that negative bacterial cultures do not prove the absence of a bacterial cause. Komaroff and his coworkers [4] found serological evidence of active infections with Chlamydia trachomatis and mycoplasma in 30% of adult patients with pharyngitis. Because these two organisms are in some circumstances susceptible to erythromycin, we hypothesize that erythromycin could reduce morbidity or the number of secondary cases or both in households of patients with nonstreptococcal pharyngitis (NSP). Thus, we initiated a double-blind, randomized, controlled trial of the efficacy of erythromycin base in adult patients with pharyngitis.

Original languageEnglish
Pages (from-to)1093-1094
Number of pages2
JournalJournal of Infectious Diseases
Volume152
Issue number5
StatePublished - 1985

Fingerprint

Pharyngitis
Erythromycin
Mycoplasma
Chlamydia trachomatis
Streptococcus
Respiratory Tract Infections
Randomized Controlled Trials
Medicine
Anti-Bacterial Agents
Morbidity
Physicians
Infection

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

MCDonald, C. J., Tierney, W. M., Hui, S., French, M. L., Leland, D. S., & Jones, R. B. (1985). A controlled trial of erythromycin in adults with nonstreptococcal pharyngitis. Journal of Infectious Diseases, 152(5), 1093-1094.

A controlled trial of erythromycin in adults with nonstreptococcal pharyngitis. / MCDonald, C. J.; Tierney, W. M.; Hui, Siu; French, M. L.; Leland, D. S.; Jones, R. B.

In: Journal of Infectious Diseases, Vol. 152, No. 5, 1985, p. 1093-1094.

Research output: Contribution to journalArticle

MCDonald, CJ, Tierney, WM, Hui, S, French, ML, Leland, DS & Jones, RB 1985, 'A controlled trial of erythromycin in adults with nonstreptococcal pharyngitis', Journal of Infectious Diseases, vol. 152, no. 5, pp. 1093-1094.
MCDonald CJ, Tierney WM, Hui S, French ML, Leland DS, Jones RB. A controlled trial of erythromycin in adults with nonstreptococcal pharyngitis. Journal of Infectious Diseases. 1985;152(5):1093-1094.
MCDonald, C. J. ; Tierney, W. M. ; Hui, Siu ; French, M. L. ; Leland, D. S. ; Jones, R. B. / A controlled trial of erythromycin in adults with nonstreptococcal pharyngitis. In: Journal of Infectious Diseases. 1985 ; Vol. 152, No. 5. pp. 1093-1094.
@article{e9e0610f786c4eddbe2402d1169661c0,
title = "A controlled trial of erythromycin in adults with nonstreptococcal pharyngitis",
abstract = "The local physician has long been maligned for profligate use of antibiotics in treating infections of the upper-respiratory-tract and pharyngitis. Academic medicine always 'knew' that the only important bacterial, and therefore treatable, cause of 'strep' pharyngitis was streptococcus. But the recent continued discovery of new and difficult-to-culture bacterial pathogens [1-3] reminds us that negative bacterial cultures do not prove the absence of a bacterial cause. Komaroff and his coworkers [4] found serological evidence of active infections with Chlamydia trachomatis and mycoplasma in 30{\%} of adult patients with pharyngitis. Because these two organisms are in some circumstances susceptible to erythromycin, we hypothesize that erythromycin could reduce morbidity or the number of secondary cases or both in households of patients with nonstreptococcal pharyngitis (NSP). Thus, we initiated a double-blind, randomized, controlled trial of the efficacy of erythromycin base in adult patients with pharyngitis.",
author = "MCDonald, {C. J.} and Tierney, {W. M.} and Siu Hui and French, {M. L.} and Leland, {D. S.} and Jones, {R. B.}",
year = "1985",
language = "English",
volume = "152",
pages = "1093--1094",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - A controlled trial of erythromycin in adults with nonstreptococcal pharyngitis

AU - MCDonald, C. J.

AU - Tierney, W. M.

AU - Hui, Siu

AU - French, M. L.

AU - Leland, D. S.

AU - Jones, R. B.

PY - 1985

Y1 - 1985

N2 - The local physician has long been maligned for profligate use of antibiotics in treating infections of the upper-respiratory-tract and pharyngitis. Academic medicine always 'knew' that the only important bacterial, and therefore treatable, cause of 'strep' pharyngitis was streptococcus. But the recent continued discovery of new and difficult-to-culture bacterial pathogens [1-3] reminds us that negative bacterial cultures do not prove the absence of a bacterial cause. Komaroff and his coworkers [4] found serological evidence of active infections with Chlamydia trachomatis and mycoplasma in 30% of adult patients with pharyngitis. Because these two organisms are in some circumstances susceptible to erythromycin, we hypothesize that erythromycin could reduce morbidity or the number of secondary cases or both in households of patients with nonstreptococcal pharyngitis (NSP). Thus, we initiated a double-blind, randomized, controlled trial of the efficacy of erythromycin base in adult patients with pharyngitis.

AB - The local physician has long been maligned for profligate use of antibiotics in treating infections of the upper-respiratory-tract and pharyngitis. Academic medicine always 'knew' that the only important bacterial, and therefore treatable, cause of 'strep' pharyngitis was streptococcus. But the recent continued discovery of new and difficult-to-culture bacterial pathogens [1-3] reminds us that negative bacterial cultures do not prove the absence of a bacterial cause. Komaroff and his coworkers [4] found serological evidence of active infections with Chlamydia trachomatis and mycoplasma in 30% of adult patients with pharyngitis. Because these two organisms are in some circumstances susceptible to erythromycin, we hypothesize that erythromycin could reduce morbidity or the number of secondary cases or both in households of patients with nonstreptococcal pharyngitis (NSP). Thus, we initiated a double-blind, randomized, controlled trial of the efficacy of erythromycin base in adult patients with pharyngitis.

UR - http://www.scopus.com/inward/record.url?scp=0022403139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022403139&partnerID=8YFLogxK

M3 - Article

VL - 152

SP - 1093

EP - 1094

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -